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Background: To investigate the nature of the research process as a whole, factors that might influence the way in
which research is carried out, and how researchers ultimately report their findings.
Methods: Semi-structured qualitative telephone interviews with authors of trials, identified from two sources: trials
published since 2002 included in Cochrane systematic reviews selected for the ORBIT project; and trial reports
randomly sampled from 14,758 indexed on PubMed over the 12-month period from August 2007 to July 2008.
Results: A total of 268 trials were identified for inclusion, 183 published since 2002 and included in the Cochrane
systematic reviews selected for the ORBIT project and 85 randomly selected published trials indexed on PubMed.
The response rate from researchers in the former group was 21% (38/183) and in the latter group was 25% (21/85).
Overall, 59 trialists were interviewed from the two different sources. A number of major but related themes
emerged regarding the conduct and reporting of trials: establishment of the research question; identification of
outcome variables; use of and adherence to the study protocol; conduct of the research; reporting and publishing
of findings. Our results reveal that, although a substantial proportion of trialists identify outcome variables based on
their clinical experience and knowing experts in the field, there can be insufficient reference to previous research in
the planning of a new trial. We have revealed problems with trial recruitment: not reaching the target sample size,
over-estimation of recruitment potential and recruiting clinicians not being in equipoise. We found a wide variation
in the completeness of protocols, in terms of detailing study rationale, outlining the proposed methods, trial
organisation and ethical considerations.
Conclusion: Our results confirm that the conduct and reporting of some trials can be inadequate. Interviews with
researchers identified aspects of clinical research that can be especially challenging: establishing appropriate and
relevant outcome variables to measure, use of and adherence to the study protocol, recruiting of study participants
and reporting and publishing the study findings. Our trialists considered the prestige and impact factors of
academic journals to be the most important criteria for selecting those to which they would submit manuscripts.
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That clinical research is important for the continued
development of healthcare provision and the wellbeing
of society is undisputed. Randomised controlled trials
(RCTs) are considered the highest level of evidence on
which to base healthcare decisions about healthcare in-
terventions, making it essential that trials are performed
and reported to the highest standards. Researchers have
a responsibility to conduct the best research they can* Correspondence: P.R.Williamson@liverpool.ac.uk
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unless otherwise stated.and publish accurate and unbiased results from it [1,2].
However, there is a large and growing body of evidence,
across many specialties of healthcare, that the current
conduct and reporting of RCTs is inadequate [3-6].
Problems associated with the conduct of research have
been linked to the lack of a structured, practical and
businesslike approach [7,8]. Problems include: trials failing
to recruit the pre-specified number of participants [8],
trials taking longer than expected to be completed [9],
and problems associated with the collection of outcome
data [10].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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atic relates to dissemination and reporting of findings.
Underreporting or selective reporting of findings has
been described as scientific misconduct [11]. Empirical
research consistently suggests that findings from pub-
lished research are more likely to be statistically significant
than those from research that remains unpublished [12].
Not reporting whole studies based on the strength and
direction of the trial results has been termed ‘publication
bias’ [13]. Reporting bias can also occur within an indi-
vidual study. For example, it may be that several out-
comes are measured but only a selected subset of them
are reported [14].
Published research articles generally provide an over-
view of the research questions, the methods used to
determine their answers and the study results. Such arti-
cles rarely reveal the practical challenges encountered by
researchers as the research progressed and how these
challenges were managed. Thus, what is missing from
the currently available literature is any account of the
reality of undertaking research with all its challenges.
Yet, it is important to know more about how trialists
understand and carry out research and to explore how
this might affect both research progress and reporting of
findings. Moreover, there is a growing recognition that
building a robust evidence base relies on trials being
conducted to the highest standards, and it is widely ac-
cepted that those high standards cannot be assumed but
have to be demonstrated by full and honest reporting of
trials [15].
Qualitative research methods are ideal for studies that
aim to explore previously unresearched topics and to
identify perceptions and uncover meanings. At the time
of designing this study, we scrutinised relevant databases
and contacted key researchers but were unable to find
any qualitative research that assessed the research pro-
cess from the viewpoint or situation of the researcher.
We therefore decided to investigate qualitatively the na-
ture of the research process as a whole and factors that
might influence the way in which research is carried out
and researchers ultimately report their findings.
The study we report here was part of a larger study in-
vestigating outcome reporting bias in clinical trials, the
ORBIT project [16]. Our focus here was on trialists’ real
life experiences of carrying out and publishing findings
from clinical trials across a range of clinical areas. The
broad aim of ORBIT was to estimate quantitatively the
prevalence and impact of outcome reporting bias in clin-
ical trials. A nine point classification system for missing
outcome data in RCTs was developed and applied to the
trials assessed in a large, unselected cohort of Cochrane
systematic reviews. Trialists were contacted and the rea-
son sought for the non-reporting of data. A sensitivity
analysis was undertaken to assess the impact of outcomereporting bias on reviews that included a single meta-
analysis of the review primary outcome. Outcome re-
porting bias was suspected in at least one RCT in more
than a third of the Cochrane systematic reviews exa-
mined [16].
The qualitative sub-study which is the focus of this
paper was performed in two distinct parts. First, we
compared original trial protocols with their linked sub-
sequent publication(s) to identify the frequency of and
reasons for selective outcome reporting and, for each
trial where selective outcome reporting was identified,
an aide memoire was produced, detailing both the pre-
specified outcomes and the published outcomes as the
focus for further discussion with the trialists concerned
during semi-structured telephone interviews. The fin-
dings from this comparison have been reported else-
where [17]. Second, trialists’ experiences of carrying out
and reporting of research more generally were also ex-
plored through the interviews; it is this latter element of
the sub-study which is reported here.
Methods
We interviewed chief or lead investigators or co-authors
of trials identified from two sources: trials published
since 2002 covered in Cochrane systematic reviews se-
lected for the ORBIT project [16]; and trial reports ran-
domly sampled from 14,758 indexed on PubMed over
the 12-month period from August 2007 to July 2008.
Each interview was tape-recorded with the trialist’s per-
mission, transcribed and anonymised. All interviews
were conducted in English by one of the investigators
(RMDS). Study methods used are described in more de-
tail elsewhere [17]. The project was not required to be
reviewed under the terms of the Governance Arrange-
ments for Research Ethics Committees in the UK as it was
considered the project came under the remit of audit/
service development.
Interview schedule
The focus of the interview schedule was on factors
influencing the way research is carried out and how
researchers report their findings. The schedule was orga-
nised sequentially, following the ‘natural history’ of a
trial, and therefore had a pre-defined structure. The in-
terview opened with questions about the main purpose
of the trial in question, how the trial outcome variables
were identified, and the use of and degree of the general
adherence to the trial protocol. This was followed by
questions relating to how the trial progressed and any
associated challenges. Trialists were also asked to de-
scribe the process of writing up the findings and trying
to get them published (including when papers were ini-
tially rejected). Additional information obtained at the
time of the interview provided a descriptive summary of
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their previous research experience, the number of re-
search sites involved in the trial under scrutiny, source
of funding, level of statistical input to the trial design
and analysis, and the planned and actual sample size.
The interview schedule is as follows:
1. General discussion about the trial as a whole - time
taken to complete the trial, role of team members,
funding, objective/motivation for doing the trial,
clinical context at the time relating to intervention
2. Regarding pre-specified outcomes - choice of
pre-specified outcomes, pre-specify 1°/2°
3. Questions relating to reporting of outcomes
(reported elsewhere)
4. Key questions relating to missing/partial reporting of
outcomes (reported elsewhere)
5. Questions relating to the writing/getting paper
published - roles of authors, statistician involvement,
decisions made regarding publishing, decisions
regarding choice of journal, journal decision,
peer review
6. Role of the protocol - writing of the protocol,
journal asked to see trial protocol, protocol used
during trial/writing up period
7. Questions relating to publication bias more
generally - ever not published (data/trial)
8. Reflecting on your experience of the trial - do
differently, lessons learnt, regrets




Interviews were taped and transcribed, and qualitative
analysis of transcripts was conducted [18]. The total num-
ber of interviews undertaken was governed by pragmatic
reasons (that is, the number of trialists approached and
agreeing to be interviewed), rather than theoretical con-
siderations (that is, attainment of data saturation). The
interview transcripts were compared and contrasted in
order to elicit information regarding the individual tria-
lists’ experiences, attitudes, perspectives, and opinions
about the broad areas of trial design, conduct and repor-
ting highlighted in the previous section. The analysis was
led by RMDS but, to reduce possible interpreter bias and
assess the plausibility and trustworthiness of the interpret-
ation of the data, interviews were independently analysed
early on by another member of the study team (AJ).The
duplicate assessments were compared by going back to
the original statements in the transcripts made by the tri-
alists to validate both sets of interpretation. Two trialists
requested, and were provided with, their interview trans-




A total of 268 trials were identified for possible inclusion
in the qualitative sub-study: 183 published since 2002 and
covered in the Cochrane systematic reviews selected for
the ORBIT project and 85 randomly selected published
trials indexed on PubMed. The response rate from re-
searchers in the former group was 21% (38/183) and in
the latter group was 25% (21/85). Overall, 59 trialists were
interviewed from the two different sources (Figure 1) [17].
Characteristics of trialists interviewed
Most interviews (48/59, 81%) were conducted with the
trial chief investigator, eight of whom were also PhD
students. A further eight interviews were conducted with
the lead author and three with a co-author. Trialists
were invited from 7 high-income countries (Australia,
Canada, Germany, the Netherlands, New Zealand, UK
and USA). All trials were performed after 1993. Trialists
varied in their level of research experience; 32 (54%) had
extensive experience and had been recruiting to trials
for many years and had run their own trials. In contrast,
six (10%) had no research experience. Just over a quarter
(28%) said that no one with statistical expertise had been
involved in the trial. Few trials (8%) recruited over 1,000
participants, most recruiting fewer than 100 participants
(47%). Funding was provided by non-commercial sour-
ces for the majority of trials (56%).
Forty-three trialists provided the full study protocol
for comparison with subsequent publication(s) by the
ORBIT sub-study team. Despite the fact that many trial-
ists highlighted the need for a formal, agreed, compre-
hensive protocol, there was wide variation in the quality
of the protocols in terms of detailing the study rationale,
proposed methods, organisation, and ethical conside-
rations, and all lacked some key information such as a
clear definition of the primary outcome or a description
of the statistical methods planned for the analysis. There
was no complete protocol available for the remaining 16
trials: six provided the ethics committee application, two
the funding application, one a summary taken from the
full protocol, and three extracts from relevant chapters
of their doctoral theses. For one trial the protocol sent
was simply a letter outlining a description of the trial
sent to the funders. For two trials the full protocol was
available, but not in English, and so an English summary
was provided. For the remaining trial we obtained an
abridged version of the protocol from the clinical trials.
gov website [17].
Characteristics of the publication(s) were compared
between trialists agreeing (n = 59) and those not agreeing
Figure 1 Trialists eligible for interview. *Includes chief or lead investigators or co-authors of trials identified from two sources: trials published
since 2002 covered in Cochrane systematic reviews and trial reports randomly sampled from 14,758 indexed on PubMed over the 12-month
period from August 2007 to July 2008.
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ists who did not agree to be interviewed were funded by
industry (82% vs 18%). There was no evidence of associ-
ation between a trialist agreeing to be interviewed and
the sample size of the trial.
The median publication year was 2005 (range 2002 to
2008). In all but one case interviews were performed with
one trial investigator from each trial; for one trial we
interviewed the chief investigator, the lead author andstatistician simultaneously at their request. Interviews lasted
on average 56 minutes (range 19 to 96 minutes).Major responses around the natural history
A number of major but related responses were identified
regarding the conduct and reporting of trials. In presen-
ting these we have ordered the data to reflect the natural
history of conducting a clinical trial, namely:
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 Role of the study protocol
 Problems with conduct of the research
 Issues around getting the research published.
Framing of the research question
All trials were conducted as a result of identification of a
clinical need or where clinicians were in clinical equipoise.
Some of the trialists were experienced researchers and
had themselves performed previous empirical research, as
a consequence their research questions were “in part
generated through our earlier work”.
Others, however, identified voids in the published re-
search literature where little or no actual research had
been performed. As a consequence, this gave the trialists
the basis on which to formulate their research questions:
“There were virtually no control studies of the
intervention, so it seemed to be a wide open
area where there is a great need to pursue
intervention” (31).
“So I discussed it with colleagues that you know
I wonder if this isn’t something that should be
tested. We looked at the research and we
couldn’t find anything published that actually
did a test” (6).
One trialist used the term equipoise spontaneously,
talking about it at an individual level and the wider com-
munity level: “We had equipoise on this subject, and we
felt that other people did not have equipoise. So there
was an international move to change policy, and intro-
duce an intervention that we felt had not been tested
and evaluated adequately” (27).
Defining key outcomes
The responses from the trialists clearly showed that pre-
specified outcome variables were generally identified
from either clinical practice or expert opinion:
“It is a very clinical question and they are
experienced clinicians who know what’s important
in the clinic” (7).
“Well we looked at the literature and we also
spoke directly to [name] - he has done more trials
with the population than anyone else, and so he
and our colleagues met with him and got his
advice about what should be measured” (37).
We asked trialists if there was a formal consensus
process in their clinical field for identifying outcomes.However, very few (n = 2) were able to base decisions
about what constituted key outcomes, as for most
they often did not exist. Others identified the role
systematic reviews play:
“I think one of the challenges with the protocol
development is us defining what an appropriate
outcome was, and I think at the time when this
was written, I think that was about 2003, there
was not yet a consensus based criteria. So at
the time that was part of the challenge in
figuring out what was a reasonable outcome
that was feasible for the study that we were
planning to conduct but actually had some
validity” (56).
“According to Cochrane analysis we must take
into account not only [outcome] and problems
of patients, but also quality of life and therefore
we added quality of life in our measurements” (2).
There was, though, evidence of some degree of gui-
dance or informal consensus within individual special-
ties which was provided by two trialists:
“Yes there are, there are recommendations or
guidelines. And there is some latitude within those
guidelines” (15).
“So in the absence of a consensus statement [....] there
probably is informal consensus” (53).
In addition to lack of consensus about whether they
were informative, relevant or important, one trialist re-
cognised different factors were dominating the selection
of outcome variables, for example ensuring the trial
would be funded:
“I think even when we were designing the protocol,
there was less consensus over whether that was an
important outcome. I think partly because if you had
omitted that I think some reviewers might have said:
‘wow you are not measuring [outcome]’. That being
said there is a vast amount of literature showing that it’s
of completely no relevance, but it was a practical
decision to make sure we got money. So I think we
were pretty ambivalent about its inclusion, and certainly
once we had analysed it we thought you know, it didn’t
really add much to the information coming out from
the paper, so we didn’t include it” (56).
Role of the study protocol
The role of the protocol was discussed in the interviews.
Authors reported differences in application of, and
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trial. Some, unsurprisingly, used the protocol to ensure
adherence to study procedures and to assist in writing
the final publication. Conversely, in some cases it was
apparent the protocol was not referred to once the trial
was in progress:
“Yes, the physicians that are participating in the trial,
yes they, they do have the protocol and they are
expected to follow the protocol clearly” (41);
“You write the protocol you spend months doing it,
and you have got a really good grasp of it and then as
the trial progresses the protocol fades, and it’s not just
in this trial, but in other trials” (59).
Regarding journals requirement of submission of the
trial protocol alongside the manuscript, three trialists had
been asked to provide their trial protocol as part of the
process. All journals had an impact factor of at least 30.
Problems with conduct of the research
Where the trialists identified problems with trial con-
duct, these were mainly surrounding recruitment diffi-
culties and the target sample size not being met. Thirteen
trialists reported that recruitment was more difficult than
expected, resulting in fewer participants being recruited,
of which four acknowledged this in their reporting, rea-
sons for which are unclear. Recruitment difficulties were
variously explained by potential participants’ lack of mo-
tivation to join the trial and over-estimation of recruit-
ment potential:
“We actually got a very high take-up rate, but
treatment as usual made the trial a bit unpopular
with some people, I think we had 60 odd who refused.
They didn’t want to be in a trial where there was a 1
in 3 chance of getting treatment as usual” (20).
“We had some difficulty with enrolment, I think
because there were less patients available than we had
envisaged at the beginning” (35).
The interviews also highlighted instances where re-
cruitment problems led to early trial closure or prompted
changes in the research design:
“We were running out of money and the recruitment
was still quite slow, so we looked at the collection of
subjects and we found no difference, it just didn’t
seem worth going on. Also, the analysis was driven by
an opportunity to present the data at a conference
and so we analysed what we had at that point, it
didn’t seem worth continuing” (5).“We changed the follow up interval [from 24 months
to 20 months] because it took us longer to do
recruitment than we thought it would. Also we
wanted to finish the study in the time line we had
funding for and decided that probably those four
months weren’t going to make a whole heck of
difference, so we compressed the timeline” (4).
Trialists also highlighted problems among trial re-
cruiters themselves. Although equipoise was generally
not expressed overtly, it appeared that clinicians were
always not uncertain about the treatment effects; and it
was apparent that some were unable to recruit par-
ticipants effectively in situations where they had some
doubts:
“It was more difficult to recruit than we had
imagined. We realised that the nurses were recruiting
in a very sort of naive way – in that they were
selecting women for the trial who they thought the
trial would work for. So they had a preconceived idea
in their head although we had spoken to them and
provided them with information” (37).
Interviews also highlighted that trial recruitment was
being stopped early based on the statistical significance
of the results at the interim analysis:
“We finished earlier because we found that there
were statistically significant differences and therefore
we didn’t continue with more than 28 patients. If
there were no statistical differences maybe we would
have asked our agency to continue funding, but we
found differences and it was good for us, very good
news for us” (2).
“The initial power calculation was for 60 patients and
after 30 patients when we analysed the data we did
see, you know a trend, benefit at 6 months so we
felt let’s publish and go for it. If I didn’t see any
differences I would have probably continued to enrol
patients – if I didn’t see anything to publish” (34).
For six trials, although the sample size was achieved it
was not without recruitment difficulties, mostly linked
to poor planning of the trial. Trialists reported problems
with participant eligibility, either because of inclusion
criteria being too tight (n = 3) or because changes in
clinical practice led to changes in the eligibility of certain
populations (n = 1):
“The percentage of people who actually agreed was
remarkably high, I think two thirds of everybody
approached agreed to be in the study. The problem was
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fairly intensive effort. We had to have teams of people
waiting in the medical offices for a person of the right
age, and that turned out to be much harder than we
had thought, and we eventually had to add more staff
and add more clinics to reach our sample size” (15).
“When we did the pilot study we were recruiting
from the emergency department and were able to get
phone consent from parents when they weren’t
present in the emergency department. Between that
trial and this trial the hospital changed its rules and
we had to have in-person signed parental consent
before we could start the assessment and intervention
with the children, and that made things a lot more
difficult in terms of recruitment and enrolment” (13).
In addition, trialists reported practical difficulties in
running a trial, either because of difficulties collecting
outcome data (n = 4), problems associated with the ran-
domisation process (n = 1), difficulty recruiting research
staff (n = 1) and revisions required post-pilot phase (n = 1).
Concerns were also raised regarding the level of adverse
outcomes, even when lower than expected:
“Even though we had said a 20% mortality for study
suspension or closure and we were not at that, it was
still felt that probably the number was too high and
there was just general concern about the extent of
early mortality in this study” (58).
“Just looking at the raw data without knowing what
treatment they were assigned, you could see there was
poor efficacy overall. So at that point we got someone
independent (statistician) to look at the data and there
was absolutely no difference at all. Then what we did
was say if there was a tiny difference do a power
calculation on how many patients you need to recruit
to see a small difference and you need something like
500 – so we knew there was no point recruiting
further patients. Together we, with the PI, we decided
there was no point going on with this. We discussed
it with the statistician and we all agreed there was no
point continuing because there was such a strong
signal that it was negative” (46).
This trialist indicates that although they were blinded
to intervention allocation they nonetheless had access to
outcome data. The trialist goes on to describe the ap-
proach taken by the study team, which was to decide as
a group to stop the trial.
In about half the trials (n = 30) there were no issues
with recruitment or retention, in three cases the sample
size being achieved earlier than expected. Some groupsperformed pilot studies, which assisted in predicting and
preventing problems prior to the trial starting. One
group had forecast recruitment difficulties but decided
to go ahead anyway, in order to secure funding (n = 1):
“The grant they gave us was the maximum so we put
together a proposal that could make best of that
knowing it was unlikely that we would achieve what
we wanted to achieve within that money, and I think
the funder knew that as well, so they were very
forthcoming when we asked for an extension” (30).
Issues around getting the research published
Trialists were asked about the process of publishing
the primary paper from the trial. Thirty-five (59%) tria-
lists had their manuscript accepted at first submission;
twenty-three had their manuscripts rejected at first sub-
mission, one trialist could not recall if accepted at first
submission. The most common reasons given by the
trialists for rejection at first submission were related to
study design (n = 13), non-significant results (n = 3), not
fitting with the topic areas of the journals approached
(n = 2), or trialists unable to recall reason/no reason by
journal given (n = 5).
Trialists reported that the impact factors of journals
and their kudos within the clinical specialty where they
worked generally dictated which journal they approached
first for publication: “It’s the most prestigious journal in
our field; it has the highest citation value of any journal in
our field” (53). Some authors were forced to opt for lower
impact factor journals due to methodological issues (that
is, ending recruitment early, or failing to recruit the pre-
specified number of patients): “For the kind of journals
which are high impact factor; unfortunately they wouldn’t
take a paper like this for two reasons – one which is valid
is that it was stopped prematurely and because it’s not
positive and negative trials are quite difficult to publish.
So the high impact journals we thought probably wouldn’t
take it” (46).
Several trialists reported feeling restricted by word
limits imposed by journals and highlighted the implica-
tions for reporting of all outcomes:
“The reviewers do not want us to report on
all the outcomes, if the journals would allow
us to publish longer papers and were interested
in reading longer papers I would be happy to
report on all possible outcomes. Secondly, there is
limitation in terms of pages, in terms of tables,
in terms of words that you can submit” (41).
For one trialist there was little guidance given by the
journal regarding what aspects of the paper were to be
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affected:
“We were asked to cut the paper, they did not give us
specific direction on what to cut they just told us to
cut it, none of the analysis were removed” (13).
A number of trialists cited problems with journal peer
review as influencing the final version of the manuscript,
one in particular citing the problem of competing inter-
ests amongst peer reviewers:
“My recollection was we had three very positive
reports and one that was very bad, and I know who
that was from, that was one of our competitors, but it
was so obvious who it was from” (38).
Other trialists acknowledged issues around study design
and inadequate sample size as problematic for publication:
“I don’t think the referees liked the fact we
didn’t have a placebo, so that was a design aspect. And
the design was actually forced on us by the funders.
Because this was a pragmatic trial, we actually put in for
a placebo controlled efficacy trial, and the [funders] told
us we should be doing an effectiveness or cost
effectiveness trial” (20).
“I think because the sample size was relatively
small, and it was a negative study so they were
concerned it wasn’t adequately powered to really
answer the question” (5).
In addition, some trialists thought that the lack of sta-
tistical significance of their findings impacted on the de-
cision by the journal not to publish:
“They declined it because it was a negative finding” (36).
“We felt, if you’ve got a negative trial that perhaps
people were less interested” (59).
One trialist discussed several issues regarding rejection
of their work, including that because the results were
negative the journal editor vetoed publication, so giving
publication bias as a suggestion of what had occurred:
“It was actually quite disappointing, we went
through two rounds of reviews and after an
extensive re-write they rejected it, and I think the
line was – you know that your work is interesting
but fundamentally your results are negative. It’s like
I know that, so it certainly was an exercise in
learning more about publication bias. I wassurprised at how blatantly the editor stated it, I
mean he just said it’s interesting but your results
are negative. At the time I was more irritated be-
cause he had wasted our time, because you know
he would have known that reading the abstract in
my first submission then we could have just ended
this, it just wasted three months of my time” (56).
In contrast, in considering their experience of getting
their work published, a number of trialists described the
constructive impact peer review had had on their manu-
scripts and felt that feedback ensured a more balanced
manuscript:
“Journal reviewers are quite helpful in getting a better
finished product. Reviewers ask important questions
and help to clarify things that as an author you have
thought were perfectly clear” (5).
“I think we probably, because the effect size was
larger in the [intervention] group, we probably made
it sound a little bit more positive in terms of our
findings, that they wanted us to make sure that we
toned it down to say that we really didn’t find many
differences and that both of these treatments were
pretty comparable in a lot of ways. I think that’s often
the case, reviewers want to make sure you don’t
claim more from your data than you can actually
support” (23).
Previous experience around publishing trial findings
All but two trialists (due to time constraints of inter-
view, n = 1; not performed a trial previously, n = 1) were
asked directly whether they had ever chosen to not pub-
lish previously conducted trials. Over half the trialists
(n = 33) stated that they themselves had never chosen
not to publish data, even when the findings were unex-
pected, negative or unfavourable:
“We have had a couple of failed studies, there was one
study, it was supposed to be a huge trial, looking to
recruit 1,800 men, and we closed after 2 years with 35
randomised, so clearly you are not going to get
anything useful out of that, but you know I badgered
and badgered and eventually we managed to write a
research letter to an international journal, where we
just presented the baseline characteristics of the
patients that joined and we talked about the
randomisation of patients and we presented some
anecdotal information about why we thought the
trial failed” (7).
Three of the 33 trialists had, however, been involved
as site investigators in industry-funded trials that were
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rience as follows:
“I can think of at least one trial that has not been
published. I was not the PI, I was just a site
investigator, that was an industry sponsored trial that
has not been published. Not only was it a negative
result but the study was stopped early because of
safety. And that has not been published” (26).
Those authors who had failed to publish any findings
from a trial (n = 16) cited many reasons: negative study
findings, lack of time, lack of resources, recruitment
problem, rejection by journals, unclear results, or failure
to complete the trial. Five trialists had published the pri-
mary, but not the secondary, outcome results:
“I have certainly not published as many papers as we
could have, but not deliberately – it’s usually lack of
the soft money that by the time you are done the
grant has run out and then you have got a new thing
starting and you know one person can’t publish all the
papers” (4).
“The major problem was we were never able to
recruit enough subjects for the study, and so the
study got terminated and we were never able to
make use of the data” (40).
Three trialists were in the process of writing up their
findings at the time of the interview, one of whom
highlighted the potential for apathy in writing up nega-
tive findings and hence a potential significant time lag
between completion and publication of negative trials:
“Well I am actually struggling with it right now. I have
an implementation trial and the results are negative and
I am pushing myself along, I am taking longer to put it
in than I should, and the paper is now drafted and we
are working on the final references so it is going to go
in, but you know I have to push myself pretty hard – I
feel bored. And then I think sometimes people are
really wedded to a hypothesis and they just don’t want
the negative results out there” (15).
Discussion
Our study adds to the scant literature on trialists’ expe-
riences of performing and publishing clinical trials in
healthcare. We set out to explore researchers’ expe-
riences and to identify which factors appeared to shape
their experiences. We have provided an insight into the
nature of the research process from the researcher’s per-
spective and our results confirm that the conduct and
reporting of some trials can be inadequate. Nonetheless,our work has identified that aspects of clinical research
can be inherently challenging.
Our work has demonstrated that a substantial propor-
tion of trialists identify outcome variables based on their
clinical experience and knowing experts in the field.
Thus our results concur with a previous study showing
insufficient reference to previous research in the plan-
ning of a new trial [19]. There appeared to be a general
lack of consensus in most clinical settings regarding
choice of appropriate outcomes. Problems associated
with lack of consensus relate to lack of clarity regarding
choice of outcome measures [20,21], outcome reporting
bias [14] and selection of outcomes that may not be mean-
ingful to clinicians [22] or health service users [23,24].
Using standardised sets of outcomes to improve the stand-
ard of reporting and make it easier for the results of trials
to be compared, contrasted and combined as appropriate
is the focus of the COMET (Core Outcome Measures in
Effectiveness Trials) Initiative [25,26].
Recruitment of participants into trials is critical for
successful trial conduct. Not reaching the target sample
size can mean that results are less reliable and so less
useful in clinical practice. However, extending the time-
frame for recruitment generally increases the costs of
trials (the longer-term impact being that fewer trials can
be conducted). However, recruiting participants to trials
can be challenging [7,27,28]. Our findings are consistent
with previous studies revealing problems with trial re-
cruitment, potential participants’ preferences, over esti-
mation of recruitment potential and recruiting clinicians
not being in equipoise. Work by others [29] has revealed
clinician barriers relating to time constraints (for ex-
ample, time pressures from usual clinical practice as well
as staffing and staff training), lack of research experience
in clinicians, adverse effect on doctor-patient relation-
ship, perceived conflict in their role as clinicians and
researchers and perceived burden of trial for patients
including travel distance and costs have all adversely af-
fected recruitment to clinical trials.
Work has been carried out to evaluate the relative ef-
fectiveness of recruitment strategies for participation in
RCTs [27]. Thirty-seven studies that compared methods
of recruiting individual study participants into an actual
trial or mock RCT were included. Strategies to increase
participant awareness of the health problem under study,
attendance at educational sessions, the addition of health
questionnaires, or a video about the health condition,
and monetary incentives were all found to improve re-
cruitment. These findings lend further support to fea-
sibility assessments and pilot trials being a potential
solution to this problem.
Conversely, the motivation of clinicians to participate in
clinical trials in the UK has also been qualitatively studied
[30]. This work reports clinicians consider having an
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potential benefits to patients (including access to treat-
ments or drugs, and closer monitoring) as opposed to pay-
ment for involvement are the most important factors [30].
High-quality protocols facilitate proper conduct, report-
ing, and external review of clinical trials [31]. However,
our results confirm that the quality of trial protocols can
be substandard. We found wide variation in the complete-
ness of protocols, especially in relation to the study ra-
tionale, the proposed methods and trial organisation, and
ethical considerations. There was also variation in the
precise definition and scope of trial protocols; 16 of our
trialists could not provide a completed comprehensive
document that included important information relating to
study design. It is now widely acknowledged that every
clinical trial requires a complete and transparent protocol
to facilitate sound trial conduct [32]. However, previous
work has confirmed the widespread deficiency in protocol
content [33-35]. In response to these shortcomings the
SPIRIT (Standard Protocol Items: Recommendations for
Interventional Trials) international initiative was deve-
loped [31,36]. This initiative aims to improve the quality
of clinical trial protocols by providing a minimum set of
scientific, ethical, and administrative elements that should
be addressed in a clinical trial protocol. The mechanism
of journals requesting protocols to be submitted alongside
the manuscript is one way of allowing a comparison of
what was planned and what was actually done.
Our trialists considered the prestige and impact factors
of academic journals to be the most important criteria
for selecting those to which they would submit manu-
scripts. This confirms work by others where the cons-
tituency of the readership, whether the journal usually
published articles on the topic, and the likelihood of manu-
script acceptance were also considered key criteria [37].
Peer reviewed publication is the final, essential step in
any research project, providing legitimisation and credit
for the work that has been done [38]. We found there
was a perception that journals were more or less inter-
ested in studies depending on the direction of the fin-
dings and the presence/absence of a so-called ‘negative’
result. In addition, several trialists experienced dif-
ficulties when writing up and getting their manuscripts
published because of word limit restrictions for paper
journals. Electronic journals allow authors to exceed the
usual paper journal word limits. In addition, open access
allows researchers to read and build on the findings of
others without restriction. The NIHR HTA programme
has a high publication rate and is the world’s first health
research funder to publish comprehensive accounts of
all of its research. The launch of the NIHR Journals
Library follows the success of the HTA journal and aims
at ensuring other participating NIHR programmes pub-
lish their research. All results are reported, whether theyare positive, negative or neutral, minimising publication
bias and maximises the usefulness of data in subsequent
studies [39]. Open access also means that teachers and
their students have access to the latest research findings
throughout the world, so acting as an important educa-
tional tool [40].
Further difficulties associated with the editorial pro-
cess were connected to peer review. There was evidence
from the trialists’ accounts that competing interests
amongst peer reviewers was a potential issue. Conflicts
of interest by peer reviewers need to be taken more ser-
iously by all [41]. Reviewers need to declare all conflicts
of interest, since competitive issues or personal relation-
ships can lead to important and less obvious bias.
Some of our trialists recognised the two principal
functions in medical journal publishing as: to select
reports for publication that meet scientific quality stan-
dards; and to improve presentation of research during
the process of revision [42]. Several investigators have
studied changes to manuscripts during the editorial
process and its impact on manuscript selection, these
being mostly related to changes in readability [43], and
the adequacy of statistical reporting [44]. Our trialists
confirmed that the peer review process had ensured
their final published manuscript was a balanced account
of the work performed. For example, it has been reported
that authors often overemphasise study findings in an at-
tempt to impress the journal with their importance [3]
and the trialists in this study acknowledged that the peer
review process allowed for the recommendation that the
findings were publishable if overstated conclusions were
toned down.
A substantial number of trialists disclosed that there
had been occasions when they had not published pre-
vious research findings. Reasons provided included nega-
tive study findings (sometimes related to not achieving
the sample size), or lack of time and resources. Our
qualitative work is consistent with previous quantitative
findings [14] revealing that not reporting a study based
on the strength and “direction” of its results - termed
publication bias - is common. Trial results should be
published whatever the outcome of the trial. However, it
was apparent from trialists’ accounts that they were
often genuinely unaware of the potential problems their
decisions not to publish could cause. Importantly, we
found no evidence of intentional wrongdoing by the tria-
lists, but rather scientific naivety. Moreover, it appeared
that the process through which trialists are required to
journey is one of negotiating hurdles and responding to
challenges that often cannot often be anticipated. Tria-
lists sometimes have to adapt their research plans, in
order to make their way through the complex research
process, and may do so with little in-depth knowledge
or formal training in research methodology.
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The strength of our study lies with its use of qualita-
tive interviews to provide real insights into the lived
experience of doing research across its natural history,
from the perspective of the investigator. Our study
adds to the evidence base on how trials are designed
and conducted in practice [45-47]. Our findings are in
accord with the issue of trial management being in-
herently complex. To review the literature, develop a pro-
tocol, apply for funding and design case report forms
requires lengthy consultations and a considered ap-
proach [7]. Studies such as ours exploring all phases of
clinical research offer transparency about the process
which, in turn, may help to identify aspects where pro-
cedures or education will help to reduce bias, improve
credibility of results and cultivate the efficient manage-
ment of trials.
We have presented the experiences of only those who
agreed to be interviewed and who, perhaps, represent re-
searchers with a particular interest in adhering to sound
research procedures. As noted earlier, a significant pro-
portion of those declining participation were funded by
the pharmaceutical industry, which may itself represent
a source of bias. Nonetheless, our trialist participants
did come from a wide range of clinical specialties, re-
search experience and countries, supporting the genera-
lisability of our findings. In addition, we acknowledge the
low acceptance rates from both sources of recruitment
(21% from Cochrane reviews selected for the ORBIT pro-
ject and 25% from randomly selected published trials
indexed on PubMed). A number of trialists declined
our offer of interview without giving a reason, which
may mean that the true picture is worse than described;
in addition there were those who were unable to locate
the trial protocol - itself suggestive of poor research
practice [17].
Conclusion
Our work has identified that aspects of clinical research
can be inherently challenging, in particular with regard
to establishing appropriate and relevant outcomes to
measure, the use of and adherence to study protocols,
recruitment of study participants and the reporting and
publishing of the study findings. To ensure clinical rele-
vance and minimise questionable research practices, it is
crucial that measures are taken to optimise the reliability
of studies that are conducted. Potential solutions to the
problems associated with poor trial design, conduct and
substandard reporting practices include: the development
of systems to support and train researchers in trial metho-
dology and processes, such as those being provided by the
UK Clinical Research Network [48], and the development
of research ‘toolkits’ such as The Clinical Trial Toolkit
[49] and The Guide to Efficient Trial Management [50].Additional means to improve trial conduct includes sup-
port from the UKCRC Registered Clinical Trials Units
(CTUs). Since 2007, all UK National Health Service trials
are strongly encouraged by funders to involve CTU ex-
pertise. The CTUs have the capability for centrally co-
ordinating multicentre clinical trials, as well as for trial
design, data management, and analysis [51]. Improving
the reporting quality of trials should include: registering
clinical trials at their inception in a publicly accessible
database [52,53]; the adoption of evidence-based reporting
guidelines, such as the CONSORT statement [54] and the
PRISMA statement [55]; an evidence-based minimum set
of reporting items in systematic reviews and meta-
analyses, in addition to research ethics committees having
a clear remit to ensure the responsible conduct of re-
search; and insistence by journal editors on the submis-
sion of a trial protocol alongside the manuscript [56].
Implementation of such strategies to support trial man-
agement will not only benefit trialists and the broader re-
search community, but also the end-users of trials, namely
the patients they seek to serve.
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